Affiliation:
1. Universidade Federal do Rio de Janeiro, Brazil
Abstract
<p>This paper reports the development, characterization and <italic>in vitro</italic>dissolution behavior of sulfasalazine suspensions for treatment of chronic intestinal inflammatory diseases. Three formulations were developed, from powdered sulfasalazine obtained from different suppliers. The sulfasalazine was characterized regarding concentration, Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), X-Ray Diffraction (XRD), particle size distribution, polydispersion and solubility. The suspensions were developed and characterized regarding pH, viscosity, density, particle size, sedimentation volume, concentration and dissolution. The pH values were slightly acidic. The method of preparing the suspensions reduced the particle sizes and made the size distribution more homogeneous. The dissolution studies showed that the sulfasalazine suspensions had low solubility in acidic media, but dissolve quickly, reaching levels of 85%, in neutral media or media containing 0.5% of surfactants such as polysorbate 80. Besides this, the sulfasalazine suspensions were classified as having immediate dissolution because they reached dissolution levels near 100% in 20 minutes.</p>
Subject
General Pharmacology, Toxicology and Pharmaceutics
Reference20 articles.
1. Resolução Diretoria Colegiada (RDC) nº 31, 11 agosto 2010. Dispõe sobre estudos de equivalência farmacêutica e de perfil de dissolução comparativo;Diário Oficial da União,2010
2. Intestinal drug solubility estimation based on simulated intestinal fluids: Comparison with solubility in human intestinal fluids;CLARYSSE S.;Eur. J. Pharm.Sci .,2011
3. Development and validation of analytical method for determination of sulfasalazine in oral suspension: comparison between spectroscopic and high performance liquid;COSTA M.A.B.;Quim. Nova,2012
4. MRP2 mediated drug-drug interaction: Indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting;DAHAN A,;Int. J. Pharm .,2010
5. The effects of Sulfasalazine treatment on enteral abnormalities of inflammatory rheumatic diseases;GENC H.;Clin. Rheumatol .,2007